ID   ALL1_ARTVU              Reviewed;         132 AA.
AC   Q84ZX5;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   27-MAR-2024, entry version 65.
DE   RecName: Full=Major pollen allergen Art v 1 {ECO:0000303|PubMed:12475905};
DE   AltName: Full=Defensin-like protein 1 {ECO:0000305};
DE   AltName: Allergen=Art v 1 {ECO:0000303|PubMed:12475905};
DE   Flags: Precursor;
OS   Artemisia vulgaris (Mugwort).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC   asterids; campanulids; Asterales; Asteraceae; Asteroideae; Anthemideae;
OC   Artemisiinae; Artemisia.
OX   NCBI_TaxID=4220;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-39, IDENTIFICATION BY
RP   MASS SPECTROMETRY, GLYCOSYLATION, ALLERGEN, AND BIOTECHNOLOGY.
RC   TISSUE=Pollen;
RX   PubMed=12475905; DOI=10.1096/fj.02-0472fje;
RA   Himly M., Jahn-Schmid B., Dedic A., Kelemen P., Wopfner N., Altmann F.,
RA   van Ree R., Briza P., Richter K., Ebner C., Ferreira F.;
RT   "Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein
RT   with a defensin-like and a hydroxyproline-rich domain.";
RL   FASEB J. 17:106-108(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALLERGEN, AND BIOTECHNOLOGY.
RC   TISSUE=Pollen;
RX   PubMed=14510717; DOI=10.1034/j.1398-9995.2003.00170.x;
RA   Bauer R., Himly M., Dedic A., Ferreira F., Thalhamer J., Hartl A.;
RT   "Optimization of codon usage is required for effective genetic immunization
RT   against Art v 1, the major allergen of mugwort pollen.";
RL   Allergy 58:1003-1010(2003).
RN   [3]
RP   STRUCTURE BY NMR OF 25-132, ALLERGEN, EPITOPE MAPPING, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF CYS-30; CYS-41; CYS-46; CYS-50; CYS-61; CYS-71; CYS-73 AND
RP   CYS-77.
RX   PubMed=20696401; DOI=10.1016/j.str.2010.05.012;
RA   Razzera G., Gadermaier G., de Paula V., Almeida M.S., Egger M.,
RA   Jahn-Schmid B., Almeida F.C., Ferreira F., Valente A.P.;
RT   "Mapping the interactions between a major pollen allergen and human IgE
RT   antibodies.";
RL   Structure 18:1011-1021(2010).
RN   [4]
RP   ALLERGEN.
RX   PubMed=29220102; DOI=10.1111/all.13375;
RA   Fu W., Gao Z., Gao L., Jin J., Liu M., Sun Y., Wu S., Wu L., Ma H.,
RA   Dong Y., Wang X., Gao B., Wang H., Akkerdaas J.H., Versteeg S.A.,
RA   van Ree R.;
RT   "Identification of a 62-kDa major allergen from Artemisia pollen as a
RT   putative galactose oxidase.";
RL   Allergy 73:1041-1052(2018).
RN   [5]
RP   ALLERGEN.
RX   PubMed=30155917; DOI=10.1111/all.13597;
RA   Gao Z., Fu W.Y., Sun Y., Gao B., Wang H.Y., Liu M., Luo F.M., Zhou X.,
RA   Jin J., Zhao L., Wu S., Liu Y., Wu L., Wang X., Tang N.B., Guo B.H.,
RA   Feng Y., Zhou J.Y., Gadermaier G., Ferreira F., Versteeg S.A., van Ree R.;
RT   "Artemisia pollen allergy in China: Component-resolved diagnosis reveals
RT   allergic asthma patients have significant multiple allergen
RT   sensitization.";
RL   Allergy 74:284-293(2019).
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:12475905}.
CC   -!- DOMAIN: Contains several extensin-like repeats in the C-terminal
CC       section. {ECO:0000305|PubMed:12475905}.
CC   -!- PTM: The mature protein extracted from the plant exhibits an average
CC       rate of 76% of hydroxyprolines. {ECO:0000305|PubMed:12475905}.
CC   -!- PTM: O-glycosylated. O-linkage of 3 galactoses plus 9-16 or 21-23
CC       arabinose residues attached on one or two hydroxyprolines.
CC       {ECO:0000269|PubMed:12475905}.
CC   -!- ALLERGEN: Causes an allergic reaction in human. Binds to IgE of mugwort
CC       pollen-sensitized patients (PubMed:12475905, PubMed:14510717,
CC       PubMed:20696401, PubMed:29220102, PubMed:30155917). Binds to IgE in 78%
CC       of the 113 Chinese patients tested (PubMed:29220102). Binds to IgE in
CC       81% of the 240 Chinese patients tested. The patients from Southwestern
CC       China have significantly lower frequency of sensitization and lower IgE
CC       levels against this protein than the patients from Northern China.
CC       Patients allergic to multiple Artemisia allergens, including Art v 1,
CC       Art v 3 and Art an 7, have a higher risk of developing allergic asthma
CC       (PubMed:30155917). Post-translational modifications might be important
CC       in the formation of epitopes recognized by IgE antibodies from allergic
CC       patients (PubMed:12475905). {ECO:0000269|PubMed:12475905,
CC       ECO:0000269|PubMed:14510717, ECO:0000269|PubMed:20696401,
CC       ECO:0000269|PubMed:29220102, ECO:0000269|PubMed:30155917}.
CC   -!- BIOTECHNOLOGY: Post-translational modifications do not seem to
CC       influence T-cell recognition. Thus, recombinant non-glycosylated Art v
CC       1 could be a starting template for engineering hypoallergenic vaccines
CC       for weed-pollen therapy (PubMed:12475905). Optimization of codon usage
CC       is required for effective genetic immunization against Art v 1 and
CC       should be considered in the development of vaccines for the treatment
CC       of allergy (PubMed:14510717). {ECO:0000269|PubMed:12475905,
CC       ECO:0000269|PubMed:14510717}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the DEFL family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF493943; AAO24900.1; -; mRNA.
DR   PDB; 2KPY; NMR; -; A=25-132.
DR   PDBsum; 2KPY; -.
DR   AlphaFoldDB; Q84ZX5; -.
DR   BMRB; Q84ZX5; -.
DR   SMR; Q84ZX5; -.
DR   Allergome; 3102; Art v 1.0101.
DR   Allergome; 753; Art v 1.
DR   EvolutionaryTrace; Q84ZX5; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0006952; P:defense response; IEA:InterPro.
DR   DisProt; DP00807; -.
DR   Gene3D; 3.30.30.10; Knottin, scorpion toxin-like; 1.
DR   InterPro; IPR003614; Scorpion_toxin-like.
DR   InterPro; IPR036574; Scorpion_toxin-like_sf.
DR   PANTHER; PTHR33147:SF157; ANTHER-SPECIFIC PROTEIN SF2-RELATED; 1.
DR   PANTHER; PTHR33147; DEFENSIN-LIKE PROTEIN 1; 1.
DR   Pfam; PF00304; Gamma-thionin; 1.
DR   SMART; SM00505; Knot1; 1.
DR   SUPFAM; SSF57095; Scorpion toxin-like; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allergen; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Secreted; Signal.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:12475905"
FT   CHAIN           25..132
FT                   /note="Major pollen allergen Art v 1"
FT                   /id="PRO_0000007033"
FT   REGION          28..77
FT                   /note="Defensin-like domain"
FT                   /evidence="ECO:0000305"
FT   REGION          64..70
FT                   /note="Epitope recognized by IgE antibodies of mugwort
FT                   pollen-sensitized patients"
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   REGION          79..87
FT                   /note="Epitope recognized by IgE antibodies of mugwort
FT                   pollen-sensitized patients"
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   REGION          81..132
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        82..132
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   DISULFID        30..77
FT                   /evidence="ECO:0000269|PubMed:20696401,
FT                   ECO:0007744|PDB:2KPY"
FT   DISULFID        41..61
FT                   /evidence="ECO:0000269|PubMed:20696401,
FT                   ECO:0007744|PDB:2KPY"
FT   DISULFID        46..71
FT                   /evidence="ECO:0000269|PubMed:20696401,
FT                   ECO:0007744|PDB:2KPY"
FT   DISULFID        50..73
FT                   /evidence="ECO:0000269|PubMed:20696401,
FT                   ECO:0007744|PDB:2KPY"
FT   MUTAGEN         30
FT                   /note="C->S: No effect on IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         41
FT                   /note="C->S: Reduces IgE reactivity 4-fold."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         46
FT                   /note="C->S: Loss of IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         50
FT                   /note="C->S: Loss of IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         61
FT                   /note="C->S: Loss of IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         71
FT                   /note="C->S: Loss of IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         73
FT                   /note="C->S: Loss of IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   MUTAGEN         77
FT                   /note="C->S: No effect on IgE reactivity."
FT                   /evidence="ECO:0000269|PubMed:20696401"
FT   STRAND          28..36
FT                   /evidence="ECO:0007829|PDB:2KPY"
FT   HELIX           44..53
FT                   /evidence="ECO:0007829|PDB:2KPY"
FT   STRAND          57..64
FT                   /evidence="ECO:0007829|PDB:2KPY"
FT   TURN            65..67
FT                   /evidence="ECO:0007829|PDB:2KPY"
FT   STRAND          68..79
FT                   /evidence="ECO:0007829|PDB:2KPY"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:2KPY"
SQ   SEQUENCE   132 AA;  13404 MW;  745249C89919F316 CRC64;
     MAKCSYVFCA VLLIFIVAIG EMEAAGSKLC EKTSKTYSGK CDNKKCDKKC IEWEKAQHGA
     CHKREAGKES CFCYFDCSKS PPGATPAPPG AAPPPAAGGS PSPPADGGSP PPPADGGSPP
     VDGGSPPPPS TH
//